These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 25814078)
21. Management of chronic myeloid leukemia in blast crisis. Saußele S; Silver RT Ann Hematol; 2015 Apr; 94 Suppl 2():S159-65. PubMed ID: 25814082 [TBL] [Abstract][Full Text] [Related]
22. The interferon-alpha revival in CML. Talpaz M; Mercer J; Hehlmann R Ann Hematol; 2015 Apr; 94 Suppl 2():S195-207. PubMed ID: 25814086 [TBL] [Abstract][Full Text] [Related]
23. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Shamroe CL; Comeau JM Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264 [TBL] [Abstract][Full Text] [Related]
24. Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. Malagola M; Breccia M; Skert C; Cancelli V; Soverini S; Iacobucci I; Cattina F; Liberati AM; Tiribelli M; Annunziata M; Trabacchi E; De Vivo A; Castagnetti F; Martinelli G; Fogli M; Stagno F; Pica G; Iurlo A; Pregno P; Abruzzese E; Pardini S; Bocchia M; Russo S; Pierri I; Lunghi M; Barulli S; Merante S; Mandelli F; Alimena G; Rosti G; Baccarani M; Russo D Am J Hematol; 2014 Feb; 89(2):119-24. PubMed ID: 24122886 [TBL] [Abstract][Full Text] [Related]
25. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S; Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930 [TBL] [Abstract][Full Text] [Related]
26. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP; N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335 [TBL] [Abstract][Full Text] [Related]
27. Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase. Rosti G; Castagnetti F; Gugliotta G; Palandri F; Baccarani M Crit Rev Oncol Hematol; 2012 May; 82(2):159-70. PubMed ID: 21565522 [TBL] [Abstract][Full Text] [Related]
28. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib. Lau A; Seiter K Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839 [TBL] [Abstract][Full Text] [Related]
30. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036 [TBL] [Abstract][Full Text] [Related]
31. Chronic myeloid leukemia: Second-line drugs of choice. Gambacorti-Passerini C; Aroldi A; Cordani N; Piazza R Am J Hematol; 2016 Jan; 91(1):67-75. PubMed ID: 26588811 [TBL] [Abstract][Full Text] [Related]
32. How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages. Breccia M; Alimena G Cancer Lett; 2012 Sep; 322(2):127-32. PubMed ID: 22450750 [TBL] [Abstract][Full Text] [Related]
33. Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia. Ault P Clin J Oncol Nurs; 2007 Feb; 11(1):125-9. PubMed ID: 17441403 [TBL] [Abstract][Full Text] [Related]
34. Advanced CML: therapeutic options for patients in accelerated and blast phases. Shah NP J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S31-S36. PubMed ID: 18397679 [TBL] [Abstract][Full Text] [Related]